Grifols SA

Grifols SA faces market volatility after a short‑seller campaign and weak earnings, yet its new cost‑control strategy and Moody’s upgrade suggest a potential turnaround amid a growing plasma‑protein market.

Grifols’ stock slump and Moody’s upgrade reveal a risky yet promising plasma‑derived biopharma; learn why investors should weigh supply, competition, and regulatory risks for a 35% upside.

Grifols SA shares see routine board‑member share transfer; no impact on strategy or governance, while market volatility from US data keeps price swings in check.

Grifols SA’s steady stock rise, strong fundamentals, and evidence‑backed plasma‑derived therapies position it ahead of peers in Spain’s pharma market.

Short‑seller Kintbury ramps up Grifols stake, sparking debate on its future amid solid market backdrop.

Grifols shares dip below €10.88 amid market volatility, facing a patent cliff for Gamunex‑C, new biosimilar plans, and strategic M&A opportunities to protect revenue and boost investor confidence.

Grifols SA: In‑depth Ibex 35 analysis uncovers modest upside, regulatory costs, emerging‑market opportunities and hidden risks for investors.

Grifols SA stays a top Spanish investor focus, drawing significant trading activity amid AI‑driven market buzz, per a 350,000‑portfolio survey.

Grifols SA wins FDA approval for its plasma‑derived fibrinogen concentrate, boosting its specialty pharma line and positioning the company for steady revenue growth in a niche market.

FDA approves Grifols SA’s plasma‑derived fibrinogen for congenital deficiency, boosting rare‑disease therapy and investor confidence.